Strides Pharma Science Q2FY26 Concall Decoded: “Margins on Steroids, Growth on Pause”
1. Opening Hook
When pharma CEOs start smiling more than surgeons, you know margins just went through the roof. Strides reported its highest-ever operational PAT and called it “consistent execution.” The CFO, though, sounded like he’d just discovered compounding for the first time. Revenue crawled, profits sprinted — the miracle of leverage, or as investors call it, “finally.”
As the Bible reminds us, “The last shall be first.” Strides’ slow revenue now leads a fast profit line. Stay tuned — because the next part’s juicier than a pharma pipeline under FDA watch. 💊
2. At a Glance
Revenue up 4.6% YoY: Slow and steady, said the tortoise to the topline.
Gross Margin 57.8%: Up 500 bps — must be some very profitable pills.
EBITDA ₹232 Cr (19% margin): CFO’s new favorite number.
PAT ₹140 Cr (record high): Company’s on a “controlled substance” of success.
Net Debt ₹1,449 Cr: Down ₹73 Cr — debt detox in progress.
Operational Cash ₹394 Cr: Converts 87% of EBITDA to real money. 💰
3. Management’s Key Commentary
“Our performance demonstrates consistent execution and sustainable growth.” (Translation: We’ve finally stopped tripping over our own API costs.)
“A 4.6% revenue increase delivered a 20x jump in PAT.” (Leverage so good, even physics would blush.)
“U.S. grew 2% YoY despite intense competition.” (Apparently, the generic wars are back, and Strides dodged most of the bullets.)
